NCT00782600CompletedPhase 1
A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Various standard descriptive pharmacokinetics endpoints including: Cmin, Cmax, Tmax, AUC.
Study Overview
Brief Summary
This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- •Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs). A BMI lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion.
- •An informed consent document signed and dated by the subject or a legally acceptable representative.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
- •Any conHistory of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
- •condition possibly affecting drug absorption (eg, gastrectomy).
Arms & Interventions
50 mg oral suspension
Experimental
once daily for one day
Intervention: suspension IR (Drug)
50 mg CR Type 1
Experimental
once daily for one day
Intervention: CR 1 (Drug)
50 mg CR Type 2
Experimental
once daily for one day
Intervention: CR 2 (Drug)
50 mg SR Type 3
Experimental
once daily for one day
Intervention: CR 3 (Drug)
Outcomes
Primary Outcomes
Various standard descriptive pharmacokinetics endpoints including: Cmin, Cmax, Tmax, AUC.
Time Frame: 1 month
Secondary Outcomes
- Safety laboratory testing including: blood electrolytes and liver and kidney function-related chemistries, complete blood counts, urinalysis, and electrocardiogram(1 month)
- Other safety parameters including: physical examination and vital signs.(1 month)
- Adverse Event Reporting as reported by subject and through investigator query and categorized by MedRA terminology.(1 month)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Early Phase 1
Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant RecipientsKidney Transplant RejectionNCT03380936University of Colorado, Denver4
Terminated
Phase 2
A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary HypertensionHypertensionNCT00444834Egalet Ltd14
Completed
Phase 1
Fast & Fed Pharmacokinetic (PK) StudyBioavailabilityNCT00692016Bayer32
Completed
Phase 3
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With SchizophreniaSchizophreniaNCT00206128AstraZeneca454
Completed
Phase 2
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDGPmm2-CDGPhosphomannomutase 2 DeficiencyNCT05549219Glycomine, Inc.27